Trials / Terminated
TerminatedNCT01640730
Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer
An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- KangLaiTe USA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kanglaite Injection | 30gm IV infusion 5 days a week for 3 weeks every 28 days |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-07-16
- Last updated
- 2014-01-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01640730. Inclusion in this directory is not an endorsement.